Pfizer’s $108 Million Verdict on AstraZeneca’s Tagrisso Survives

A Pfizer Inc. unit’s $107.5 million verdict will stand, as a federal judge rejected AstraZeneca Plc’s request for a new trial after a Delaware jury found AstraZeneca’s blockbuster cancer drug Tagrisso infringes two patents for Pfizer’s competing Vizimpro.

Wyeth LLC’s US Patent Nos. 10,603,314 and 10,596,162 aren’t unenforceable or invalid for indefiniteness, according to Judge Matthew F. Kennelly’s findings of fact and conclusions of law issued Tuesday in the US District Court for the District of Delaware.

• Kennelly rejected AstraZeneca’s defenses of unclean hands, implied waiver, and patent misuse, adding that “even if AstraZeneca had satisfied the elements of one ...